Rafael Holdings Reports Fiscal Year 2026 Financial Results
The Newark-based company posted a $29.6 million net loss while facing questions regarding its future as a going concern.
Updated on Oct. 29, 2026 in Corporate Finance
Live Poll
Do you trust biotechnology companies to succeed despite recent financial losses and failed clinical trials?
Rafael Holdings announced a net loss of $29.6 million for the fiscal year that ended July 31, 2026. The firm faces substantial doubt regarding its ability to continue as a going concern despite holding $22.1 million in cash and cash equivalents.
Why it matters
The company reported higher annual research and development costs driven by a $13.4 million increase in spending related to Cyclo Therapeutics. Simultaneously, Cyclo Therapeutics submitted a New Drug Application to the FDA for remibetadex.
Rafael Holdings reported a fourth-quarter net loss of $9.2 million, or $0.18 per share. Total general and administrative expenses for the year reached $9.7 million after the firm reduced payroll and professional fee costs.
The players
Rafael Holdings
This Newark-based company focuses on developing pharmaceutical products and managing various clinical-stage assets.
Cyclo Therapeutics
This biotechnology firm specializes in developing targeted treatments for Niemann-Pick disease and other rare disorders.
FDA
This federal agency is responsible for reviewing and approving new drug applications for commercial use in the United States.
MIT
This academic research institution licensed hydroxypropyl-β-cyclodextrin technology to Rafael Holdings in April 2026.
The details
Although the Phase 3 TransportNPC study failed to meet its primary endpoint in the total patient population, a prespecified analysis indicated a 71 percent slowing of disease progression in a specific subgroup. The company also benefited from a $4.4 million gain on the settlement of accounts payable and convertible notes.
Timeline
April 2026: Cyclo licensed Alzheimer's treatment technology from MIT.
June 2026: The Phase 3 TransportNPC study was completed.
June 2026: An investigator-initiated Phase II trial for Promitil launched in Israel.
July 31, 2026: The fiscal year ended for Rafael Holdings.
October 28, 2026: The NDA for remibetadex was submitted to the FDA.
Market Landscape
The firm is navigating the transition from clinical testing to the formal regulatory review cycle established by the FDA New Drug Application process. This milestone is central to the broader industry trend of consolidating development pipelines to achieve commercial viability.
Investors and stakeholders are monitoring how the company manages its limited cash reserves to fund ongoing clinical development. The firm's ability to maintain operations depends on its success in transitioning its research assets through the regulatory pipeline.
The takeaway
The company's future remains tied to the success of its regulatory applications and clinical subgroup outcomes. Shareholders should continue to monitor the firm's liquidity levels against its ongoing research and development obligations.
Further reading
For additional context on fiscal filings, see the latest Corporate Finance reports.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust biotechnology companies to succeed despite recent financial losses and failed clinical trials?
